Status | Study |
Recruiting |
Study Name: Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) Condition: Urinary Tract Infection (UTI) Complicated Urinary Tract Infection Date: 2016-03-30 Interventions: Drug: MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g |
Recruiting |
Study Name: Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli Condition: Infection Due to Escherichia Coli Acute Pyelonephritis Date: 2015-08-02 Interventions: Drug: Sitafloxacin The patient |
Completed |
Study Name: A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) Condition: Complicated Urinary Tract Infection Acute Pyelonephritis Date: 2015-06-25 Interventions: Drug: plazomicin Drug: meropenem |
Terminated |
Study Name: Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Condition: Acute Pyelonephritis(APN) Date: 2014-07-13 Interventions: Drug: Omega-3 Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 21 |
Completed |
Study Name: Effect of Acetylcysteine in Pediatric Acute Pyelonephritis. Condition: Pyelonephritis Date: 2014-02-28 Interventions: Drug: Acetylcysteine Drug: placebo acetylc |
Recruiting |
Study Name: Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection Condition: Acute Pyelonephritis Date: 2014-01-10 |
Completed |
Study Name: L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Condition: Acute Pyelonephritis(APN) Date: 2013-09-21 Interventions: Drug: L-carnitine 50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antib |
Completed |
Study Name: Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Condition: Urinary Tract Infections Acute Pyelonephritis Date: 2013-07-17 Interventions: Drug: Finafloxacin 800 mg i.v. once daily |
Terminated |
Study Name: Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli Condition: Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli Date: 2013-02-19 Interventions: Drug: Cefoxitin proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for |
Completed |
Study Name: Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis Condition: Pyelonephritis Date: 2012-07-12 Interventions: Other: No intervention There is no intervention |